Advancing Pharmacoequity Globally: Reflections from the <scp>ASCPT</scp> Development, Regulatory, and Outcomes Network

ASCPT has a mission to advance clinical pharmacology and translational sciences to reduce health disparities. The development, regulatory, and outcomes (DRO) network within ASCPT strives to advance pharmacoequity globally. Pharmacoequity, coined by Utibe Essien (2021), is the principle that all individuals, regardless of race, ethnicity, geography, or socioeconomic status, should have access to high-quality and evidence-based therapies. This perspective spotlights the network's contributions toward this goal and identifies priority areas to build equitable health outcomes.

Authors

Institutions

Publication Details

Journal
Clinical Pharmacology & Therapeutics
Published
2026-02-13
DOI
https://doi.org/10.1002/cpt.70237
Primary Topic
Biomedical Ethics and Regulation
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Advancing Pharmacoequity Globally: Reflections from the ASCPT Development, Regulatory, and Outcomes Network

Juyao Dong, Long Tao, Aarti Sawant‐Basak, Rob Christiaan van Wijk et al.
Clinical Pharmacology & Therapeutics
Biomedical Ethics and Regulation
article

Advancing Pharmacoequity Globally: Reflections from the ASCPT Development, Regulatory, and Outcomes Network

Juyao Dong, Long Tao, Aarti Sawant‐Basak, Rob Christiaan van Wijk, Jatinder Kaur Mukker, Noha Rayad, Georgios Vlasakakis, Katarina Ilić, Mohamed A. Elmeliegy, Priya Jayachandran, the DRO Network, Mayur K. Ladumor, Tao Zhang, Andrew Riselli
article en

Abstract

ASCPT has a mission to advance clinical pharmacology and translational sciences to reduce health disparities. The development, regulatory, and outcomes (DRO) network within ASCPT strives to advance pharmacoequity globally. Pharmacoequity, coined by Utibe Essien (2021), is the principle that all individuals, regardless of race, ethnicity, geography, or socioeconomic status, should have access to high-quality and evidence-based therapies. This perspective spotlights the network's contributions toward this goal and identifies priority areas to build equitable health outcomes.

Clinical Pharmacology & Therapeutics
Binghamton University (US), Pfizer (United States) (US), Regeneron (United States) (US), United States Military Academy (US), AbbVie (United States) (US), AstraZeneca (South Korea) (KR), GlaxoSmithKline (United States) (US), AstraZeneca (Brazil) (BR), Centre for Human Drug Research (NL), Takeda (United States) (US), Gilead Sciences (United States) (US), AstraZeneca (Canada) (CA), International Drug Development (FR), Merck Serono S.p.A. (Italy) (IT)
Regeneron Pharmaceuticals
Openalex Percentile: Top 54%
Biomedical Ethics and Regulation
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.